Needham Maintains Buy on Viridian Therapeutics, Raises Price Target to $42

Benzinga · 12/23/2025 10:46
Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $34 to $42.